New: NCI-funded clinical trial search
Mednet Logo
SpecialtiesRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How would you manage a metastatic lesion abutting the optic structures (globe, optic nerve, etc)?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Columbia University Irving Medical Center

Generally, if I'm treating a metastatic lesion abutting an OAR - in this case, it's an optic nerve - I try to keep my Dmax to the optic nerve/chiasm to 8 Gy (allow up to 10 Gy if needed). If I can't achieve those constraints, I would favor fractionated radiosurgery. There are some papers looking at ...

In the setting of single or multi-fraction cranial radiosurgery, do you have different constraints for the dose to the optic tract just posterior to the chiasm, compared to the constraints for the chiasm?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Montreal

I treat the post-chiasmatic tract the same as the pre-chiasmatic nerve segments in a single x-shaped structure. As for the optic striations, as they blend into the brain, they get treated the same as the rest of the brain.

Would you treat T1a glottic cancer with single vocal cord irradiation using IGRT?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Michigan

Treating glottis larynx ca with IMRT/VMAT sparing the carotid artery has been reported by several institutions and is straightforward (for example, here). The benefits are supposed to be reduced cerebrovascular events, however, the utility of this approach is unknown, taking into account the relativ...

Do you prescribe silvadene cream for patients with a sulfa allergy?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cancer Care Centers of Brevard

No. I will consider hydrogel wound dressings in those situations

What is your preferred method for adding bolus, at CT sim or virtual bolus?

3
5 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

Absolutely, should always apply at sim. Gives you an opportunity to work out the appropriate positioning of the patient to optimize bolus conformality and to select the appropriate bolus type (frequently Superflab but often you don’t know until you get the patient on the sim table whether custom mol...

Is ENI necessary for postoperative treatment of clinically N0 adenoid cystic carcinoma of the head and neck?

5
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Maryland School of Medicine

Adenoid cystic carcinoma (ACC) is an uncommon malignancy of the head and neck characterized by an intermediate growth rate and a propensity for local recurrence, perineural tumor spread, and distant metastasis. Historically thought to be radioresistant, patients were treated with surgery alone until...

Is it ever appropriate to omit temozolomide in unmethylated glioblastoma?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Florida International University

Perhaps a different perspective on this question would be which unmethylated patients would you be willing to not treat with up-front temozolomide? The genesis of the question and conundrum comes from the modest benefit described in the above-mentioned trials for this subgroup. As Hegi herself descr...

How do you manage oxaliplatin-induced splenomegaly?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic

Oxaliplatin can lead to sinusoidal obstructive syndrome (SOS), which will result in portal hypertension. Splenomegaly is one of the portal hypertension signs.The SOS is correlated with cumulative oxaliplatin dose, and cumulative dose >1000 mg/m2 is considered a potential threshold (Overman et al., P...

What is the role of adjuvant RT for metastatic RCC to the thyroid resected with high-risk features?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · New Vision University

There is no established role for adjuvant radiotherapy after thyroidectomy for RCC metastases, even with high-risk features. Most published evidence consists of small retrospective series or case reports. When RT is used, it’s generally for palliation. That said, selected high-risk cases (positive m...

What are your top takeaways from ASCO GI 2025?

2
8 Answers

Mednet Member
Mednet Member
Medical Oncology · Stanford University Medical Center

1. BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer. This ambitious phase 3 randomized trial is an initiative of project frontrunner to attempt to allow access of targeted therapy in earlier lines of treatment for advanced ca...